Compare Quest Diagnostics Inc (DGX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Noble Corporation plc — how do they compare? Quest Diagnostics Inc trades at $231.5 (market cap $25.48B), while Noble Corporation plc trades at $42.57 (market cap $6.73B). The key difference: Quest Diagnostics Inc is far larger — about 3.8× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Noble Corporation plc for 26 Days on average.
| DGX | NE | |
|---|---|---|
Market Cap | $25.48B | $6.73B |
Volume | 941,866 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $247.45 | $54.37 |
52-Week Low | $173.49 | $26.70 |
Typical Hold Time | 56 Days | 26 Days |
Enterprise Value | $31.23B | $8.16B |
Dividend Yield | 1.49% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
Noble Corporation (NE) trades at $40.97, down 1.16% today, with a bearish technical outlook. The stock shows mixed earnings performance with recent misses but maintains positive cash flow. Analyst consensus is divided with a $52 price target suggesting 27% upside. Recent news includes a long-term drilling contract with Tullow in Ghana, extending utilization into 2027.
The outlook remains cautious due to ongoing legal investigations and volatile earnings. While valuation appears reasonable with EV/EBITDA of 8.79, declining revenue and profit margins pose challenges. The dividend provides income support, but investors face execution risks amid mixed analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
